Amarantus Therapeutics, Inc., a privately
held biotechnology company developing first-in-class disease-modifying
treatments that address the underlying cause of cell death, today announced
its participation in the OneMedForum 2010 Emerging Company Finance
Conference on Tuesday, January 12, 2010. The conference is being held at
the Sir Francis Drake Hotel in San Francisco. Martin D. Cleary, Chairman
and CEO, will present an overview of Amarantus on Tuesday, January 12, 2010
at 2:25 p.m. PST.

To listen to the audiocast of the presentation live or a replay of the
event, please visit the company's web site at www.amarantustherapeutics.com

Amarantus Therapeutics, Inc. also announced that the company has appointed
Vern Norviel, J.D. to the position of Corporate Secretary. Mr. Norviel is a
partner at Wilson Sonsini Goodrich & Rosati, where he leads the firm's
patents and innovation counseling practice. Joining the Board of Directors
is Kenneth L. Coleman, Chairman of Accelrys, Inc., a leading software
provider to the biotechnology industry, and Gene Mancino, a founding
partner in Mancino Burfield Edgerton LLP., a life sciences executive search
firm.

"We are pleased to welcome Kenneth, Gene and Vern to the Company at this
critical stage in Amarantus Therapeutics' growth," said Mr. Cleary. "All
three are highly respected in their sectors and strengthen our solid team,
providing a good balance of scientific, business and legal experience."

Mr. Norviel previously served as general counsel and corporate secretary of
Perlegen Sciences, Inc., senior vice president and general counsel at
Affymetrix, Inc., and partner at Townsend & Townsend & Crew LLP in Palo
Alto. Vern has more than two decades of experience in formulating
successful strategies for life science companies and the development of
their IP programs. During his career, he has authored or prosecuted more
than 15 patents that have been litigated in the United States and abroad,
and has overseen intellectual property lawsuits throughout the world.

Mr. Coleman is founder, former Chairman and CEO of ITM Software (sold to
BMC Corp.). Previously, he was executive vice president of global sales,
service and marketing for Silicon Graphics, Inc. and vice president of
product development at Activision, Inc. Mr. Coleman currently serves on the
boards of Accelrys, City National Bank, MIPS Technologies and United
Online. He earned both a bachelors and a masters degree from The Ohio State
University. He also served as a captain in the United States Air Force.

Mr. Mancino has been involved in the life sciences industry since 1979. He
advises both development stage and fully integrated biopharmaceutical
companies with respect to operational management, strategic leadership and
corporate governance. He is currently a Business Advisor to Creative
BioVentures LLC, a Board Member at Fish Nature, Inc, and Limited Partner at
Mediphase Venture Partners and Taraval Associates LLC. Gene earned an AB
degree from Princeton University.

About Amarantus Therapeutics, Inc.

Amarantus Therapeutics, Inc. is a privately held biotechnology company
developing first-in-class disease-modifying treatments that address the
underlying cause of cell death, known as apoptosis, associated with a wide
range of diseases, including neurodegenerative and cardiovascular.
Amarantus Therapeutics' most advanced drug candidate, AMRS001, is a growth factor indicated for the treatment of
Parkinson's disease and Myocardial Infarction. Additional information is
available at www.amarantustherapeutics.com.